TIMP2 gene polymorphisms are associated with hypertension in patients with myocardial infarction
暂无分享,去创建一个
M. Vallejo | J. Fragoso | G. Vargas-Alarcón | T. Juárez-Cedillo | C. Posadas-Romero | J. Rodríguez-Pérez | N. Pérez-Hernández | I. Monroy-Muñoz | E. Kimura-Hayama | N. Martinez–Rodriguez
[1] Dong Hwan Kim,et al. Association between IL10, IL10RA, and IL10RB SNPs and ischemic stroke with hypertension in Korean population , 2013, Molecular Biology Reports.
[2] R. Vasan,et al. Biomarkers of Extracellular Matrix Metabolism (MMP-9 and TIMP-1) and Risk of Stroke, Myocardial Infarction, and Cause-Specific Mortality: Cohort Study , 2011, PloS one.
[3] Qi Zhang,et al. Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[4] S. K. Kim,et al. Promoter Polymorphism (rs3755724, -55C/T) of Tissue Inhibitor of Metalloproteinase 4 (TIMP4) as a Risk Factor for Kawasaki Disease with Coronary Artery Lesions in a Korean Population , 2009, Pediatric Cardiology.
[5] Satwat Hashmi,et al. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. , 2008, The Canadian journal of cardiology.
[6] H. Markus,et al. Polymorphisms in MMP Family and TIMP Genes and Carotid Artery Intima-Media Thickness , 2007, Stroke.
[7] B. Horne,et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. , 2007, American heart journal.
[8] Toshiro Hara,et al. Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease. , 2007, The Journal of pediatrics.
[9] Aiqing He,et al. The Unfolded Protein Response Is an Important Regulator of Inflammatory Genes in Endothelial Cells , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[10] Chia-Hung Liu,et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization , 2006, Nucleic Acids Res..
[11] Leslie L. Clark,et al. Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease , 2006, Circulation.
[12] A. Sterpetti,et al. Metalloproteinases and their inhibitors are markers of plaque instability. , 2005, Surgery.
[13] David Handelsman,et al. Androgens and cardiovascular disease. , 2003, Endocrine reviews.
[14] H. Mabuchi,et al. Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis , 2001, Clinical chemistry and laboratory medicine.
[15] J. Ye,et al. Cloning of the human tissue inhibitor of metalloproteinase-4 gene (TIMP4) and localization of the TIMP4 and Timp4 genes to human chromosome 3p25 and mouse chromosome 6, respectively. , 1998, Genomics.
[16] A. Bowcock,et al. Structure and Characterization of the Human Tissue Inhibitor of Metalloproteinases-2 Gene* , 1996, The Journal of Biological Chemistry.
[17] H. Stöhr,et al. Genomic organization of the human tissue inhibitor of metalloproteinases-3 (TIMP3) , 1995, Genome research.
[18] J. McEwan,et al. Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.
[19] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[20] J. Nurnberger,et al. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. , 1991, Nucleic acids research.
[21] R. Tjian,et al. Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro , 1988, Nature.
[22] R. Punnett,et al. The journal of genetics , 1910, Zeitschrift für Induktive Abstammungs- und Vererbungslehre.
[23] Stefan Agewall,et al. Matrix metalloproteinases and cardiovascular disease. , 2006, European heart journal.
[24] A. Newby,et al. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.
[25] F Matzkies,et al. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat. , 1996, Kidney international.